Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: helping to treat IFIs
in the ICU1,12
in the ICU1,12
Liposomal Amphotericin B was chosen to help treat
Yusuf’s Aspergillus infection because it demonstrates*:
Yusuf’s Aspergillus infection because it demonstrates*:
*The clinical relevance of these animal studies in humans is unknown.16
**Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 2
Aspergillus confirmed
DAY 3-14
Yusuf's outcome
A significantly improved clinical safety profile
vs. other forms of amphotericin B**13–21
vs. other forms of amphotericin B**13–21
Compared with conventional amphotericin B, the liposomal
delivery of Liposomal Amphotericin B has been shown to
reduce nephrotoxicity (p=0.046)†14, the frequency of
infusion‑related reactions (p<0.001)‡13 and hypokalaemia
(p=0.02).§13 These factors may positively impact
the length of hospital stay when compared to
conventional amphotericin B.13–21
delivery of Liposomal Amphotericin B has been shown to
reduce nephrotoxicity (p=0.046)†14, the frequency of
infusion‑related reactions (p<0.001)‡13 and hypokalaemia
(p=0.02).§13 These factors may positively impact
the length of hospital stay when compared to
conventional amphotericin B.13–21
Fungicidal activity vs. Aspergillus
fumigatus and Aspergillus flavus
fumigatus and Aspergillus flavus
Liposomal Amphotericin B demonstrates fungicidal
activity against most clinically important yeast and
moulds.22–25
activity against most clinically important yeast and
moulds.22–25
Efficacy as a first-line therapy
Liposomal Amphotericin B has demonstrated efficacy as
first-line therapy for proven or probable invasive
aspergillosis other mould infections (EORTC/MSG
criteria) in a variety of at‑risk patients.¶26
first-line therapy for proven or probable invasive
aspergillosis other mould infections (EORTC/MSG
criteria) in a variety of at‑risk patients.¶26
View footnotes to proceed
